NEW FINDINGS: What is the topic of this review? Carotid body chemoreceptor activity is tonically elevated in heart failure and contributes to morbidity due to the reflex activation of sympathetic nerve activity and destabilization of breathing. The potential causes for the enhanced chemoreceptor activation in heart failure are discussed. What advances does it highlight? The role of a chronic reduction in blood flow to the carotid body due to cardiac failure and its impact on signalling pathways in the carotid body is discussed. Recent advances have attracted interest in the potential for carotid body (CB) ablation or desensitization as an effective strategy for clinical treatment and management of cardiorespiratory diseases, including hypertension, heart failure, diabetes mellitus, metabolic syndrome and renal failure. These disease states have in common sympathetic overactivity, which plays an important role in the development and progression of the disease and is often associated with breathing dysregulation, which in turn is likely to mediate or aggravate the autonomic imbalance. Evidence from both chronic heart failure (CHF) patients and animal models indicates that the CB chemoreflex is enhanced in CHF and contributes to the tonic elevation in sympathetic activity and the development of periodic breathing associated with the disease. Although this maladaptive change is likely to derive from altered function at all levels of the reflex arc, a tonic increase in afferent activity from CB glomus cells is likely to be a main driving force. This report focuses on our understanding of mechanisms that alter CB function in CHF and their potential translational impact on treatment of CHF.
NEW FINDINGS: What is the topic of this review? Carotid body chemoreceptor activity is tonically elevated in heart failure and contributes to morbidity due to the reflex activation of sympathetic nerve activity and destabilization of breathing. The potential causes for the enhanced chemoreceptor activation in heart failure are discussed. What advances does it highlight? The role of a chronic reduction in blood flow to the carotid body due to cardiac failure and its impact on signalling pathways in the carotid body is discussed. Recent advances have attracted interest in the potential for carotid body (CB) ablation or desensitization as an effective strategy for clinical treatment and management of cardiorespiratory diseases, including hypertension, heart failure, diabetes mellitus, metabolic syndrome and renal failure. These disease states have in common sympathetic overactivity, which plays an important role in the development and progression of the disease and is often associated with breathing dysregulation, which in turn is likely to mediate or aggravate the autonomic imbalance. Evidence from both chronic heart failure (CHF) patients and animal models indicates that the CB chemoreflex is enhanced in CHF and contributes to the tonic elevation in sympathetic activity and the development of periodic breathing associated with the disease. Although this maladaptive change is likely to derive from altered function at all levels of the reflex arc, a tonic increase in afferent activity from CB glomus cells is likely to be a main driving force. This report focuses on our understanding of mechanisms that alter CB function in CHF and their potential translational impact on treatment of CHF.
Authors: Rui-Fang Yang; Jing-Xiang Yin; Yu-Long Li; Matthew C Zimmerman; Harold D Schultz Journal: Am J Physiol Cell Physiol Date: 2010-10-27 Impact factor: 4.249
Authors: Yanfeng Ding; Yu-Long Li; Matthew C Zimmerman; Harold D Schultz Journal: Am J Physiol Regul Integr Comp Physiol Date: 2009-11-18 Impact factor: 3.619
Authors: Yanfeng Ding; Yu-Long Li; Matthew C Zimmerman; Robin L Davisson; Harold D Schultz Journal: Cardiovasc Res Date: 2008-12-17 Impact factor: 10.787
Authors: David C Andrade; Alexis Arce-Alvarez; Camilo Toledo; Hugo S Díaz; Claudia Lucero; Rodrigo A Quintanilla; Harold D Schultz; Noah J Marcus; Markus Amann; Rodrigo Del Rio Journal: Am J Physiol Heart Circ Physiol Date: 2017-11-22 Impact factor: 4.733
Authors: Wioletta Pijacka; Davi J A Moraes; Laura E K Ratcliffe; Angus K Nightingale; Emma C Hart; Melina P da Silva; Benedito H Machado; Fiona D McBryde; Ana P Abdala; Anthony P Ford; Julian F R Paton Journal: Nat Med Date: 2016-09-05 Impact factor: 53.440
Authors: Philip D Coblentz; Bumsoo Ahn; Linda F Hayward; Jeung-Ki Yoo; Demetra D Christou; Leonardo F Ferreira Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-01-31 Impact factor: 5.464